Vertex’s povetacicept shows strong proteinuria reduction in Phase 3 IgA nephropathy trial, FDA accepts BLA
+1 new source since this summary was written
Vertex Pharmaceuticals reported that povetacicept lowered 24‑hour urinary protein‑to‑creatinine ratio by about 52 % in the interim analysis of its Phase 3 RAINIER trial, far exceeding the 4.3 % change seen with placebo. The FDA has accepted the biologics license application for accelerated approval, setting a PDUFA target date of 30 Nov 2026. The trial met its primary endpoint and safety was comparable to placebo. The data were presented in the New England Journal of Medicine and at the American Society of Nephrology conference.
Why it matters
If the FDA grants accelerated approval, Vertex could add a first‑in‑class therapy for IgA nephropathy, potentially expanding its revenue base and supporting the VRTX share price. The acceptance of the BLA also signals regulatory confidence in the trial’s results.
Key facts
- 1Povetacicept reduced 24‑hour urinary protein‑to‑creatinine ratio by 52.0 % at week 36 versus a 4.3 % increase with placebo. hcplive.com
- 2The adjusted between‑group difference in UPCR change at week 36 was –49.8 percentage points (95 % CI –58.6 to –39.2). hcplive.com
- 3The FDA accepted Vertex’s Biologics License Application for accelerated approval with a PDUFA target action date of 30 Nov 2026. hcplive.com
- 4The interim efficacy analysis included 199 participants (131 on povetacicept, 68 on placebo). hcplive.com
- 5The trial met its primary endpoint, achieving a 52.0 % reduction from baseline in proteinuria at week 36. investing.com
- 6Adverse events occurred in 75 % of povetacicept recipients versus 78 % of placebo recipients; serious adverse events were 3 % versus 4 %. hcplive.com
Open questions
- Material 1 reports a 52.0 % proteinuria reduction versus placebo 4.3 %, while Material 2 states a 49.8 % reduction compared to placebo, creating a conflict on the exact magnitude of benefit.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.